Zobrazeno 1 - 10
of 59
pro vyhledávání: '"D. Brock Hewitt"'
Publikováno v:
Annals of Surgery Open, Vol 3, Iss 3, p e178 (2022)
Externí odkaz:
https://doaj.org/article/653fd509dc5a43fbacc947fda7e1626e
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 3, p 085 (2022)
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer behind hepatocellular carcinoma (HCC) and carries a dismal prognosis. Improved genetic analysis has paved the way for a better understanding of the distinct somatic
Externí odkaz:
https://doaj.org/article/1c510e7a6d8b413db85eef0c3048dbff
Autor:
Zachary J. Brown, Azarakhsh Baghdadi, Ihab Kamel, Hanna E. Labiner, D. Brock Hewitt, Timothy M. Pawlik
Publikováno v:
HPB. 25:14-25
Choledochal cysts (CCs) are rare cystic dilatations of the intrahepatic and/or extrahepatic bile ducts. We review the pathophysiology, diagnosis, and management of CCs.MEDLINE/PubMed and Web of Science databases were queried for "choledochal cyst", "
Publikováno v:
The American Journal of Surgery.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Expert Opinion on Investigational Drugs. 31:693-706
Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapy options. Since the approval of sorafenib in 2008, no systemic therapy has provided a sustained/robust/survival benefit for patients with advanced HCC unt
Autor:
Dimitrios Papaconstantinou, D. Brock Hewitt, Zachary J. Brown, Dimitrios Schizas, Diamantis I. Tsilimigras, Timothy M. Pawlik
Publikováno v:
Expert Review of Anticancer Therapy. 22:297-306
HCC comprises roughly 60 to 80% of all primary liver cancers and exhibits wide geographical variability. Appropriate treatment allocation needs to include both patient and tumor characteristics.Current HCC classification systems to guide therapy are
Autor:
Gaya Spolverato, Dajana Glavas, D. Brock Hewitt, Zachary J Brown, Giulia Capelli, Francesca Bergamo, Mario Domenico Rizzato, Timothy M. Pawlik
Publikováno v:
Expert Opinion on Pharmacotherapy. 23:473-481
Cholangiocarcinomas (CCA) are rare, highly invasive tumors often diagnosed at an advanced disease stage with an associated poor prognosis. Surgery represents the only chance for curative-intent treatment, but recurrence rates remain high. Neoadjuvant
Publikováno v:
Expert Opinion on Investigational Drugs. 31:379-391
Introduction : Unfortunately, some hepatocellular carcinoma (HCC) patients do not qualify for curative-intent treatments such as surgical resection or transplantation. Hence, locoregional treatments such as transarterial chemoembolization (TACE) rema
Publikováno v:
Annals of Surgical Oncology. 29:3363-3365